This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Tilidine is a synthetic opioid indicated in the treatment of severe pain.
- Generic Name
- Tilidine
- DrugBank Accession Number
- DB13787
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Tilidine (DB13787)
- Weight
- Average: 273.376
Monoisotopic: 273.172878985 - Chemical Formula
- C17H23NO2
- Synonyms
- Tilidate
- Tilidine
- External IDs
- DEA No. 9750
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Severe pain Combination Product in combination with: Naloxone (DB01183) •••••••••••• ••••••••• ••••••• •••••••• ••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Tilidine is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Tilidine. Acetophenazine The risk or severity of hypotension and CNS depression can be increased when Acetophenazine is combined with Tilidine. Aclidinium The risk or severity of adverse effects can be increased when Aclidinium is combined with Tilidine. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Tilidine. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Tilidine fumarate DXT828600R 55567-81-2 PMBFJKOESQBPHB-BHDCFXIMSA-N Tilidine hydrochloride 4YI72J28N9 27591-69-1 MUWDJVKYGSDUSH-KALLACGZSA-N Tilidine hydrochloride hemihydrate Y757T3419R 255733-17-6 WHYVWQHDUOALSV-UMJMSJQKSA-N Tilidine phosphate PJ7Z0WL915 157163-65-0 UYYDHBMJHNMKRC-KPVRICSOSA-N - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image TILICOMP BETA 100/8MG RET Tilidine hydrochloride (100 mg) + Naloxone hydrochloride (8 mg) Tablet, extended release Oral 2010-04-01 Not applicable Germany 
TILICOMP BETA 100/8MG RET Tilidine hydrochloride (100 mg) + Naloxone hydrochloride (8 mg) Tablet, extended release Oral 2010-04-01 Not applicable Germany TILICOMP BETA 100/8MG RET Tilidine hydrochloride (100 mg) + Naloxone hydrochloride (8 mg) Tablet, extended release Oral 2010-04-01 Not applicable Germany TILICOMP BETA 150/12MG RET Tilidine hydrochloride (150 mg) + Naloxone hydrochloride (12 mg) Tablet, extended release Oral 2010-04-01 Not applicable Germany TILICOMP BETA 150/12MG RET Tilidine hydrochloride (150 mg) + Naloxone hydrochloride (12 mg) Tablet, extended release Oral 2010-04-01 Not applicable Germany
Categories
- ATC Codes
- N02AX51 — Tilidine and naloxoneN02AX01 — Tilidine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Amines
- Direct Parent
- Aralkylamines
- Alternative Parents
- Benzene and substituted derivatives / Trialkylamines / Carboxylic acid esters / Amino acids and derivatives / Monocarboxylic acids and derivatives / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Amino acid or derivatives / Aralkylamine / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Monocyclic benzene moiety
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- ethyl 2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate (CHEBI:77822)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- GY33N31E9Y
- CAS number
- 51931-66-9
- InChI Key
- WDEFBBTXULIOBB-WBVHZDCISA-N
- InChI
- InChI=1S/C17H23NO2/c1-4-20-16(19)17(14-10-6-5-7-11-14)13-9-8-12-15(17)18(2)3/h5-8,10-12,15H,4,9,13H2,1-3H3/t15-,17+/m1/s1
- IUPAC Name
- ethyl (1S,2R)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate
- SMILES
- CCOC(=O)[C@@]1(CCC=C[C@H]1N(C)C)C1=CC=CC=C1
References
- General References
- DIMDI Product Information: VALORON (naloxone and tilidine) oral [Link]
- External Links
- ChemSpider
- 27988
- 10597
- ChEBI
- 77822
- ChEMBL
- CHEMBL2104560
- ZINC
- ZINC000002014722
- Wikipedia
- Tilidine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, extended release Oral Solution Oral Solution / drops; suspension / drops Ophthalmic 0.1 % - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.181 mg/mL ALOGPS logP 3.16 ALOGPS logP 3.35 Chemaxon logS -3.2 ALOGPS pKa (Strongest Basic) 8.6 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 29.54 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 82.16 m3·mol-1 Chemaxon Polarizability 30.75 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 161.2642 predictedDeepCCS 1.0 (2019) [M-H]- 161.2642 predictedDeepCCS 1.0 (2019) [M+H]+ 163.62222 predictedDeepCCS 1.0 (2019) [M+H]+ 163.62222 predictedDeepCCS 1.0 (2019) [M+Na]+ 170.45377 predictedDeepCCS 1.0 (2019) [M+Na]+ 170.45377 predictedDeepCCS 1.0 (2019)
Drug created at June 23, 2017 20:48 / Updated at April 18, 2024 08:44